Suppr超能文献

男性乳腺癌患者近 30 年的生存状况。

Survival in male breast cancer over the past 3 decades.

机构信息

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.

Grupo Oncológico Cooperativo del Sur (GOCS), Neuquén, Argentina.

出版信息

J Natl Cancer Inst. 2023 Apr 11;115(4):421-428. doi: 10.1093/jnci/djac241.

Abstract

BACKGROUND

Breast cancer mortality in women has declined statistically significantly over the past several years. In men, it is unclear whether survival has changed over time. We evaluated changes in breast cancer-specific survival (BCSS) and overall survival (OS) in male breast cancer over the past 3 decades.

METHODS

We evaluated men diagnosed with breast cancer between 1988 and 2017, reported in the Surveillance, Epidemiology, and End Results registry. Patients were categorized into 3 groups by year of diagnosis: 1988-1997, 1998-2007, and 2008-2017. BCSS and OS were estimated by Kaplan-Meier, and differences between groups were compared by log-rank test. Multivariable Cox regression evaluated the independent association of year of diagnosis with BCSS and OS. All tests were 2-sided.

RESULTS

We included 8481 men. Overall, BCSS at 5 years was 83.69%, 83.78%, and 84.41% in groups 1988-1997, 1998-2007, and 2008-2017, respectively (P = .86). There was no statistically significant difference in BCSS between the 3 groups within each stage of disease. Among all patients, OS at 5 years was 64.61%, 67.31%, and 69.05% in groups 1988-1997, 1998-2007, and 2008-2017, respectively (P = .01). In adjusted Cox models, each additional year of diagnosis had no statistically significant association with BCSS (hazard ratio = 1.00, 95% confidence interval = 0.99 to 1.01, P = .75), but there was statistically significant improvement in OS (hazard ratio = 0.99, 95% CI = 0.98 to 0.99, P = .009).

CONCLUSIONS

Over the past 3 decades, there has been no statistically significant improvement in BCSS in male breast cancer. Changes in OS over time are consistent with increasing life expectancy. Efforts to improve BCSS in male breast cancer are warranted.

摘要

背景

过去几年,女性乳腺癌死亡率已呈明显统计学下降。但男性乳腺癌的生存率是否随时间变化尚不清楚。本研究评估了过去 30 年来男性乳腺癌的乳腺癌特异性生存率(BCSS)和总生存率(OS)的变化。

方法

我们评估了 1988 年至 2017 年间在监测、流行病学和最终结果登记处诊断为乳腺癌的男性患者。患者按诊断年份分为 3 组:1988-1997 年、1998-2007 年和 2008-2017 年。通过 Kaplan-Meier 评估 BCSS 和 OS,并通过对数秩检验比较组间差异。多变量 Cox 回归评估诊断年份与 BCSS 和 OS 的独立关联。所有检验均为双侧。

结果

共纳入 8481 例男性患者。总体而言,1988-1997 年、1998-2007 年和 2008-2017 年组的 5 年 BCSS 分别为 83.69%、83.78%和 84.41%(P=.86)。在每个疾病阶段,3 组之间的 BCSS 无统计学显著差异。在所有患者中,1988-1997 年、1998-2007 年和 2008-2017 年组的 5 年 OS 分别为 64.61%、67.31%和 69.05%(P=.01)。在调整后的 Cox 模型中,每增加 1 年诊断与 BCSS 无统计学显著关联(风险比=1.00,95%置信区间=0.99 至 1.01,P=.75),但 OS 有统计学显著改善(风险比=0.99,95%CI=0.98 至 0.99,P=.009)。

结论

过去 30 年来,男性乳腺癌的 BCSS 无统计学显著改善。OS 随时间的变化与预期寿命的增加一致。需要努力改善男性乳腺癌的 BCSS。

相似文献

1
Survival in male breast cancer over the past 3 decades.
J Natl Cancer Inst. 2023 Apr 11;115(4):421-428. doi: 10.1093/jnci/djac241.
2
Effect of Age on Breast Cancer Patient Prognoses: A Population-Based Study Using the SEER 18 Database.
PLoS One. 2016 Oct 31;11(10):e0165409. doi: 10.1371/journal.pone.0165409. eCollection 2016.
5
Effect of lymph node metastasis size on breast cancer-specific and overall survival in women with node-positive breast cancer.
Breast Cancer Res Treat. 2015 Jul;152(1):209-216. doi: 10.1007/s10549-015-3451-y. Epub 2015 Jun 4.
7
Association of statin use with clinical outcomes in patients with triple-negative breast cancer.
Cancer. 2021 Nov 15;127(22):4142-4150. doi: 10.1002/cncr.33797. Epub 2021 Aug 3.
8
Trend and survival benefit of contralateral prophylactic mastectomy among men with stage I-III unilateral breast cancer in the USA, 1998-2016.
Breast Cancer Res Treat. 2021 Dec;190(3):503-515. doi: 10.1007/s10549-021-06397-z. Epub 2021 Sep 23.
9
The role of adjuvant chemotherapy in stage I-III male breast cancer: a SEER-based analysis.
Ther Adv Med Oncol. 2020 Sep 20;12:1758835920958358. doi: 10.1177/1758835920958358. eCollection 2020.

引用本文的文献

4
6
Unraveling complexity and leveraging opportunities in uncommon breast cancer subtypes.
NPJ Breast Cancer. 2025 Jan 24;11(1):6. doi: 10.1038/s41523-025-00719-w.
7
The features of male breast cancer in China: A real-world study.
Breast. 2024 Aug;76:103762. doi: 10.1016/j.breast.2024.103762. Epub 2024 Jun 22.

本文引用的文献

1
Efficacy of neoadjuvant chemotherapy in male breast cancer compared with female breast cancer.
Cancer. 2022 Nov 1;128(21):3796-3803. doi: 10.1002/cncr.34448. Epub 2022 Sep 7.
2
Gene expression predicts dormant metastatic breast cancer cell phenotype.
Breast Cancer Res. 2022 Jan 29;24(1):10. doi: 10.1186/s13058-022-01503-5.
3
Cancer statistics, 2022.
CA Cancer J Clin. 2022 Jan;72(1):7-33. doi: 10.3322/caac.21708. Epub 2022 Jan 12.
5
Tumor subtypes and survival in male breast cancer.
Breast Cancer Res Treat. 2021 Aug;188(3):695-702. doi: 10.1007/s10549-021-06182-y. Epub 2021 Mar 26.
6
Trends in male breast cancer mortality: a global overview.
Eur J Cancer Prev. 2021 Nov 1;30(6):472-479. doi: 10.1097/CEJ.0000000000000651.
9
Management of Male Breast Cancer: ASCO Guideline.
J Clin Oncol. 2020 Jun 1;38(16):1849-1863. doi: 10.1200/JCO.19.03120. Epub 2020 Feb 14.
10

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验